Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12588924 | 0.91 | GAA (0.42) | GAAOPRM1OPRD1OPRK1 | |
| SCHEMBL10066077 | 0.84 | GAA (0.54) | GAAOPRM1OPRD1OPRK1MAPT | |
| SCHEMBL18458095 | 0.84 | GAA (0.45) | GAAOPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL12646375 | 0.83 | GAA (0.52) | GAAOPRM1OPRD1OPRK1 | |
| SCHEMBL10033224 | 0.82 | GAA (0.54) | GAAOPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL12646269 | 0.82 | GAA (0.51) | GAAOPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL10222586 | 0.81 | OPRM1 (0.55) | GAAOPRM1OPRD1OPRK1 | |
| SCHEMBL28925147 | 0.76 | GAA (0.70) | GAAOPRM1OPRD1OPRK1MAPT | |
| SCHEMBL12945025 | 0.76 | GAA (0.38) | GAAALDH1A1 | |
| SCHEMBL6123801 | 0.75 | GAA (0.46) | GAAOPRM1OPRD1OPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2453895-B1 | (+) - MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-9562014-B2 | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof | MALLINCKRODT LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20170029432-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT ENTERPRISES LLC | 2017-02-02 | — | — | US | disclosed |
| US-20150335638-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | STRATATECH CORPORATION | 2015-11-26 | — | — | US | disclosed |
| US-20110136845-A1 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof | MALLINCKRODT INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110015219-A1 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof | MALLINCKRODT INC. (US) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029432-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | TLR9, TLR3, TLR7 | GAA 1100/4885OPRM1 5/4885OPRD1 13/4885 |
| US-20110136845-A1 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof | TLR9, TLR3, TLR7 | GAA 1100/4885OPRM1 5/4885OPRD1 13/4885 |
| US-20150335638-A1 | (+)-MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | TLR9, TLR3, TLR7 | GAA 1006/4885OPRM1 30/4885OPRD1 141/4885 |
| US-20110015219-A1 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof | TLR9, TLR3, TLR1 | GAA 2289/4885OPRM1 17/4885OPRD1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.